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Background
Prime-boost strategies are thought to increase the durabil-
ity and the breadth of vaccine induced responses and we
have recently shown that the use of a novel DNA vector,
auxo-GTU®-MultiHIV-B is able to induce high level and
long-lasting HIV specific T-cell responses in macaques. In
addition, lipopeptides based on a palmitoyl group can
efficiently process and present peptides by dendritic cells
to CD8+T cells and have been shown immunogenic in
animal models and in human.
The objective of this study was to boost auxo-GTU®-Mul-
tiHIV-B induced T-cell responses with lipopeptides based
HIV-1 vaccine after 2 years of last DNA vaccine injection.
Methods
Cynomolgus macaques were primed with three (weeks 0,
4 and 12) intradermal injections (ID) with or without
electroporation of auxo-GTU®-MultiHIV-B DNA vector.
Animals received two distant booster injections of a
multi-component vaccine composed of 5 HIV LAI
lipopeptides containing peptides derived from HIV-1
Gag, Nef and Pol proteins.
Results
ID with auxo-GTU-MultiHIV-B DNA followed by EP
induced IFNγ producing cells lasting for 3 years after the
last plasmid injection. Production of IFNγ by PBMC was
observed in response to all injected lipopeptides. After a
single injection of Lipo5, we observed an increase in IFNγ
production of PBMC against Gag17-35 and Gag253-284
lipopeptides in auxo-GTU-MultiHIV-B primed animals. A
second Lipo5 injection increased these responses and
induced IFNγ responses against Nef66-97 and Nef116-
145 lipopeptides. Furthermore, we observed that two
injections of Lipo5 were sufficient to induce IFNγ
response against the 5 studied lipopeptides in one naïve
macaque indicating that Lipo5 can prime an HIV specific
response in macaques.
Conclusion
HIV-1 based lipopeptides are able to induce poly-epitopic
T-cell responses in macaques and efficiently boost
responses primed two years ago by DNA vaccination.
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